✓ Dispatched same or next working day · 2–3 day UK delivery
Commonly combined with ChemAesthetic Selank Nasal 10mg in research protocols.
Ratings are based on published research data and are for informational purposes only.
Selank is a synthetic heptapeptide derived from tuftsin, developed in Russia and studied as an anxiolytic and nootropic agent. It modulates GABAergic, serotonergic, and dopaminergic signalling without the sedative or dependence liability of benzodiazepines. Nasal administration achieves rapid CNS penetration due to the direct olfactory pathway.
Research Post
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, with a Pro-Gly-Pro extension for stability) is a synthetic heptapeptide derived from the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg). Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has been the subject of substantial Russian preclinical and Phase II/III clinical research, primarily examining anxiolytic and cognitive-enhancing properties.
Tuftsin is an endogenous tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc fragment of IgG and produced primarily in the spleen. It has known immunomodulatory, phagocytosis-stimulating, and mild CNS-active properties. Selank was designed by appending a Pro-Gly-Pro tripeptide extension that dramatically increases plasma stability by inhibiting degradation by prolyl oligopeptidase and other peptidases, extending functional half-life from minutes to hours while preserving and enhancing the parent peptide's activity profile.
Selank's anxiolytic effects appear mediated through multiple mechanisms. GABA-A receptor modulation has been proposed based on benzodiazepine-like behavioural effects in rodent anxiety models (elevated plus-maze, open field). However, unlike benzodiazepines, Selank does not produce sedation or muscle relaxation at anxiolytic doses, and tolerance development appears limited in animal models — properties of considerable research interest.
Serotonin system interaction has also been characterised: Selank upregulates expression of serotonin receptors and increases serotonin metabolism in the hippocampus and hypothalamus in rodent studies. Additionally, Selank has been shown to normalise expression of BDNF (brain-derived neurotrophic factor) in animal anxiety models, suggesting a neuroplasticity mechanism complementary to its acute anxiolytic effects.
Beyond anxiety, Selank has been studied for cognitive effects. Russian preclinical data demonstrates improvements in learning, memory consolidation, and attention in rodent models. The BDNF upregulation mechanism is particularly relevant here: BDNF is a critical mediator of synaptic plasticity, long-term potentiation, and hippocampal neurogenesis. Selank-induced BDNF increases in the prefrontal cortex and hippocampus may underlie observed cognitive improvements.
Enkephalin system interactions have also been reported: Selank appears to inhibit enzymes that degrade Met-enkephalin, increasing endogenous opioid peptide activity. This has been proposed as a secondary mechanism for both anxiolytic and mood-related effects.
Reflecting its tuftsin origins, Selank has characterised immunomodulatory effects. It stimulates macrophage phagocytic activity, modulates T-lymphocyte proliferation, and affects expression of immune-relevant cytokines including IL-6 and interferon. Russian clinical data reports beneficial effects in patients with immune deficiency states. The immunological and neurological effects may be related: cytokine signalling (particularly IL-6 and TNF-α) is increasingly recognised as relevant to anxiety, depression, and cognitive function through neuroinflammatory pathways.
Selank was registered as a pharmaceutical in Russia and has been used clinically for anxiety and asthenic disorders. Phase II/III trials conducted at Russian research institutes demonstrated efficacy in generalised anxiety disorder comparable to benzodiazepines, with superior side effect profiles (no sedation, no dependence). While these data have not been published in Western peer-reviewed journals with full methodology, they form the basis of Selank's clinical use in Russia and provide context for its research profile.
Intranasal administration allows direct transport to the CNS via the olfactory nerve pathway, bypassing the blood-brain barrier and achieving higher brain concentrations than peripheral routes. Selank's small peptide size makes it suitable for intranasal delivery, and both injectable and intranasal formulations have been studied.
